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The Right to Try: Expanded Access for the Terminally Ill in Clinical Trials  
Abigail Burroughs was nineteen years old when she was diagnosed with head and neck 
cancer.1. Abigail underwent the conventional treatments for her disease, including chemotherapy 
and radiation therapy.2 A year into her treatment, her doctors had exhausted all standard 
therapies but Abigail’s condition had not improved. As a final attempt to save or prolong her life, 
Abigail’s oncologist recommended that she attempt to enroll in a clinical trial for two 
unapproved drugs that he believed she might benefit from.3 The drug targeted the same receptors 
as her cancer but it was only being studied in patients with colon cancer.4 With her health 
deteriorating, Abigail was denied access to the trial because she did not meet the strict scientific 
criteria for inclusion.5 
Several months later she was accepted into a trial for a third unapproved study, by the 
time she was granted access, Abigail was too ill to travel and passed away at the age of 21.6 
Following her death, her father founded the Abigail Alliance for Better Access to Developmental 
Drugs (“Abigail Alliance”) to advocate for increased access to unapproved drugs for terminally 
ill patients.7 
Since 1987, the Food and Drug Administration (“FDA”) has had rules in place that give 
terminally ill patients the opportunity to access drugs or biologics that are still in development 
                                                     
1 Abigail Alliance for Better Access to Developmental Drugs v. Von Eschenbach, 469 F.3d 470 
(2006).  
2 Id. 
3 Id.  
4 Id. 
5 Id. 
6 Id. 
7 The Abigail Alliance Mission, ABIGAIL ALLIANCE FOR BETTER ACCESS TO DEVELOPMENTAL 
DRUGS, (last visited October 15, 2010), http://www.abigail-alliance.org.  
and pending approval to be used for treatment purposes.8 Investigational or experimental drugs 
are new drugs that have not yet been approved by the FDA and are in the process of being tested 
for safety and effectiveness.9 Patients may decide to seek access to investigational drugs for 
different reasons. Some patients, with serious or life-threatening illnesses, like Abigail, seek 
treatment with investigational drugs if FDA-approved therapies are not working or if their side 
effects are too severe.10 Others may be encouraged to learn more if they heard of positive early 
study results for a specific investigational drug.11 
Gaining access to these drugs is very difficult. In an attempt to ensure safety and adequacy of 
the research, the FDA enforces tight restrictions on who can participate in clinical trials. Patients 
and families dealing with terminal illness have attempted to assert a fundamental right in order to 
gain access to these unapproved therapies. For patients that have exhausted all other therapies, 
these investigational drugs can provide a final chance to fight for their lives. The issue of 
terminally ill patients' access to clinical trials and experimental drugs received increased public 
attention when it reached the U.S. Supreme Court in 2008. The court declined to review a federal 
appeals court decision that held that terminally ill patients do not have a constitutional right to 
obtain investigational drugs before the FDA has approved them.12  
The issue also reached Congress in 2008 when Senator Sam Brownback (R-Kan.) introduced 
the “Access, Compassion, Care and Ethics for Seriously Ill Patients Act” (the “ACCESS Act”) 
that would serve to increase terminally ill patients' access to promising treatments in the 
                                                     
8 FDA Expands Access to Investigational Drugs, FDA (Aug. 12, 2009), 
http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm176845.htm 
9 Id.  
10 Id. 
11 Id. 
12 Gunvalson v. PTC Therapeutics, Inc., 303 Fed. Appx. 128 (3d Cir. N.J. 2008). 
investigational phase of FDA approval.13 The bill would allow patients to have access to 
promising new drugs and devices once Phase I clinical trials have been completed.14 Under 
current law, patients with life-threatening diseases may only receive access to treatments that 
have completed Phase II clinical trials.  
Subsequently, in 2009, to ensure “broad and equitable access to investigational drugs for 
treatment” the FDA amended these expanded access program rules.15 An investigational drug 
may pose unknown risks to patients and it is uncertain if the drug will be effective, therefore, 
these drugs are available through two pathways specifically designed to protect patients.16 
Patients may be eligible to receive an investigational drug as a participant in a clinical trial or as 
part of an expanded access program; this is also known as compassionate use.17 
Terminally ill patients, like Abigail, present a sympathetic claim for access to unapproved 
therapy when such access is the last hope for the patient. In the interest of patient autonomy and 
increased scientific knowledge, terminally ill patients should be granted expanded access to 
clinical trials. The current regulations that exist regarding patient access to unapproved drugs and 
the debate over a terminally ill patient’s constitutional right to access experimental drugs prior to 
FDA approval create obstacles for these patient’s that are fighting to save their lives.  
I.  Clinical Trials  
 The Federal Food, Drug, and Cosmetic Act (“FDCA”) authorizes agency rulemaking, 
which gives the FDA the authority to set rules to implement and explain the provisions of the 
                                                     
13 Kurt Karst, Access Act Reintroduced by Sen. Brownback; Previous Tiered Approval 
Nomenclature Scrapped and New Immunity Provision Add, FDA LAW BLOG (June 4, 2008, 11:15 
AM), http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2008/06/access-act-rein.html.  
14 Id.  
15 Access to Investigational Drugs Outside of a Clinical Trial (Expanded Access), FDA (Feb. 24, 
2014),http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/AccesstoInvestigati
onalDrugs/ucm176098.html/ 
16 Id. 
17 Id. 
FDCA. The FDA has the authority to regulate human drugs under the FDCA.18 Regulation of 
human drugs includes manufacturing controls for quality purposes, labeling controls for 
consumer protection, and a premarket approval process for new drugs to determine safety and 
efficacy using a risk-benefit approach.19 
The Center for Drug Evaluation and Research is responsible for the evaluation of safety 
and efficacy of brand name and generic prescription and over-the-counter drugs.20 They are also 
responsible for the advertising of prescription drugs and post-market monitoring of drug products 
for risks and adverse events.21 Through pre- and post-marketing phases, human drugs and 
medical devices are the most heavily regulated consumer products by the FDA.22 
 The development of new and investigational drugs follows three phases when testing in 
humans. Testing in animals, which always precedes human testing, is also a requirement for 
FDA drug approval and is referred to as Phase O or “Preclinical” testing.23 
There are a number of Pre-Approval Phases involved in bringing a new drug to the 
market. The first phase is the preclinical investigation phase, consisting of laboratory and animal 
testing.24 This does not require FDA prior notification. Following the successful completion of 
preclinical testing, an investigational new drug (“IND”) application must be filed prior to 
initiation of clinical trials, including a general investigative plan, clinical trial protocols, 
                                                     
18 Jordan Paradise et. al., Evaluating Oversight of Human Drugs and Medical Devices: A Case 
Study of the FDA and Implications for Nanobiotechnology, 37 MED. & ETHICS J.L 598 (2009). 
19 Id.  
20 How Drugs are Developed and Approved, FDA (Feb. 13, 2014) 
http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/ 
21 Id. 
22 Id. 
23 Jordan Paradise et. al., Evaluating Oversight of Human Drugs and Medical Devices: A Case 
Study of the FDA and Implications for Nanobiotechnology, 37 MED. & ETHICS J.L 598 (2009). 
24 Id. at 601. 
information on proposed drug chemistry, pharmacology, toxicology, and manufacturing and 
controls, and a summary of previous human experience with the drug.25 
There are three key phases to clinical trials. The first phase typically involves approximately 
20-80 healthy participants using escalating doses of the drug in order to determine preliminary 
safety and tolerability data, metabolism, pharmacologic action and side effects.26 In part, this is 
one reason why Phase I testing is usually done in healthy individuals as opposed to terminally ill 
patients. The objectives of Phase I trials are to gain an understanding of the side effects of new 
drugs, determine how the drug affects the targeted disease in patients and observe the patient 
response to the drug.27 Phase I trials only enroll a small number of participants.28 Trial 
participants are divided into small groups, known as cohorts; the first cohort receives a low dose 
of the new drug. Doctors may collect blood or urine samples to measure drug levels in the 
patients.29 If the first cohort does not have any severe side effects, then a new cohort receives a 
higher dose of the same drug.30 The dose increases until the trial investigators find the best dose 
for future testing. With each increasing dose, doctors test each patient to see if he or she is 
responding to the treatment.31 If the doctors find that the treatment is safe, then it will advance to 
a Phase II of the clinical trial. 
Phase II involves up to several hundred patients with the disease or condition under study 
and should obtain initial evidence of effectiveness against the targeted disease, explore further 
                                                     
25 Id.  
26 Id. 
27 What are Phase 1 Clinical Trials? MD ANDERSON CANCER CENTER (last visited Apr. 2014), 
HTTP://WWW.MDANDERSON.ORG/PATIENT-AND-CANCER-INFORMATION/CARE-CENTERS-AND-
CLINICS/CLINICS/CLINICAL-CENTER-FOR-TARGETED-THERAPY/WHAT-ARE-PHASE-1-CLINICAL-
TRIALS/INDEX.HTML 
28 Id. 
29 Id. 
30 Id. 
31 Id. 
risks and side effects, and confirm preliminary data on optimal doses.32 Phase III involves 
thousands of people at many different locations and can be initiated after appropriate notification 
to FDA and gathering of preliminary efficacy data.33 
The primary goal of a clinical trial is to collect data necessary to meet safety and efficacy 
standards required for FDA approval.34 In addition to these three phases of the clinical trials, the 
FDA can require the sponsor to undertake post-approval Phase IV studies in order to secure 
further data.35 Throughout the clinical trial phases, sponsors and investigators are obligated to 
obtain valid informed consent, elect appropriate investigators, adhere to protocols, maintain 
accurate and up-to-date records, engage in appropriate shipping and handling of products and 
report adverse events.36 
Participating in a clinical study contributes to medical knowledge.37 The results of these 
studies can make a difference in the care of future patients by providing information about the 
benefits and risks of therapeutic, preventative, or diagnostic products or interventions.38 
Some trials may provide participants with the prospect of receiving direct medical benefits, 
while others do not.39 Most trials involve some risk of harm or injury to the participant, although 
it may not be more than the risks related to routine medical care or disease progression.40 Many 
trials require participants to undergo additional procedures, tests, and assessments based on the 
                                                     
32 Id. 
33 Id. 
34 The FDA's Drug Review Process: Ensuring Drugs Are Safe and Effective, FDA (Apr. 25, 
2014) http://www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm. 
35 Id. 
36 Id. 
37 U.S. Nat’l. Inst. of Health, Learn About Clinical Studies, CLINICALTRIALS.GOV (last reviewed 
Aug. 2012), http://www.clinicaltrials.gov/ct2/about-studies/learn. 
38 Id.  
39 Id. 
40 Id. 
study protocol.41 These are described to the patient in the informed consent document for a 
particular trial; a potential participant should also discuss these issues with members of the 
research team and with his or her usual health care provider.42 
The length of a clinical study varies, depending on what is being studied. It can take 10 to 15 
years or more to complete all three phases of clinical trials before the licensing stage.43 This time 
span can vary greatly depending on certain factors, such as the type of disease, the type of 
treatment, the number of patients needed, the length of the treatment, the follow up period and 
any problems that arise with the new drug.44 
Accelerating the development and availability of drugs that treat serious diseases is desirable, 
especially when the drugs are the first available treatment or can provide advantages over 
existing treatments.45  Life-Saving treatments can be expedited through the accelerated approval 
(fast track) and treatment INDs. Treatment INDs enable the use of an investigational drug 
outside of clinical trials in order to treat patients with serious or immediately life-threating 
diseases for which no comparable or alternative therapy is available.46 
Surrogate endpoints are another mechanism in new drug approval. This approach is 
beneficial when the clinical trial would be dangerous to the patients or take an impractically long 
time to complete. It is based on an assumption about the adequacy of the endpoint to signal 
                                                     
41 Id. 
42 Id. 
43 How long does it take for a new drug to go through clinical trials?, CANCER RESEARCH UK 
(Oct. 9, 2013), http://www.cancerresearchuk.org/cancer-help/about-cancer/cancer-
questions/how-long-does-it-take-for-a-new-drug-to-go-through-clinical-trials#long%29. 
44 Id. 
45 Fast Track, Breakthrough Therapy, Accelerated Approval and Priority Review, FDA (June 26, 
2013),http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/speedingaccesstoimport
antnewtherapies/ucm128291.htm. 
46 Id. 
safety and efficacy.47 
The primary intent of expanded access is to provide treatment for a patient’s disease or 
condition, rather than to collect data about the study drug. There are many benefits to allowing 
patient participation in expanded access programs. Expanded access can provide access to 
patients with serious or life-threatening disease who have no other alternatives and may be 
willing to accept greater risk. EAPs can provide patients a measure of autonomy over their own 
health care decisions.48 The treatment IND can help bridge the gap between the latter stages of 
product development and approval by making a drug widely available during that period and 
expanded access use can help foster development of additional uses of a drug.49 An example of 
this would be anecdotal evidence of benefit in a disease other than that being studied. Though the 
primary purpose would not be to necessarily to advance the research of the drug, allowing 
expanded access could have this effect while providing hope for patients with no other options.50 
II. Regulation of Access  
The use of investigational drugs for treatment purposes is legal, but it is tightly restricted to 
patients who meet certain conditions. As previously discussed, the FDA regulations on access 
specify the criteria for patients to qualify for access to the clinical trials and expanded use 
programs.  
The FDA must determine that the patient or patients to be treated have a serious or 
immediately life-threatening disease or condition, and there is no comparable or satisfactory 
                                                     
47 Id. 
48 RICHARD KLEIN, Expanded Access Programs, FDA (Mar. 1, 2012), 
http://www.fda.gov/downloads/ForIndustry/DevelopingProductsforRareDiseasesConditions/OO
PDNewsArchive/UCM294794.pdf. 
49 Id. 
50 Id. 
alternative therapy to diagnose, monitor, or treat the disease or condition.51 The potential patient 
benefit must justify the potential risks of the treatment use and those potential risks must not be 
unreasonable in the context of the disease or condition to be treated.52 Finally, providing the 
investigational drug for the requested use must not interfere with the initiation, conduct, or 
completion of clinical investigations that could support marketing approval of the expanded 
access use or otherwise compromise the potential development of the expanded access use.53 
The FDA defines an “immediately life-threatening disease or condition” as a stage of disease 
in which there is a reasonable likelihood that death will occur within a matter of months or in 
which premature death is likely without early treatment.54 “Serious disease or condition” is 
defined as a disease or condition associated with morbidity that has substantial impact on day-to-
day functioning.55 Short-lived and self-limiting morbidity will usually not be sufficient, but the 
morbidity need not be irreversible, provided it is persistent or recurrent.56 Whether a disease or 
condition is serious is a matter of clinical judgment, based on its impact on such factors as 
survival, day-to-day functioning, or the likelihood that the disease, if left untreated, will progress 
from a less severe condition to a more serious one.57 
A company sponsoring a drug in the late stages of drug development, such as Phase III 
clinical trials, can offer expanded access programs for patients who are not able to enroll in a 
clinical trial.58 The FDA generally approves these expanded access programs if the drug has 
                                                     
51 21 C.F.R. §312.305 (2013). 
52 Id. 
53 Id. 
54 21 C.F.R. §312.300 (2013). 
55 Id. 
56 Id. 
57 Id. 
58 Clinical Trials: What You Need to Know, AMERICAN CANCER SOCIETY (last revised Sept. 21, 
2012),http://www.cancer.org/treatment/treatmentsandsideeffects/clinicaltrials/whatyouneedtokno
waboutclinicaltrials/index.htm?sitearea=eto 
shown that it works at least somewhat to treat cancer in the clinical trials that are being done.59 
This can allow a lot of people access to the unapproved drug, as long as they meet the 
requirements of the EAP. 
Expanded access, sometimes called "compassionate use,” is the use of an investigational 
drug outside of a clinical trial to treat a patient with a serious or immediately life-threatening 
disease or condition who has no comparable or satisfactory alternative treatment options.60  
FDA regulations allow access to investigational drugs outside of clinical trials for treatment 
purposes on a case-by-case basis for an individual patient, or for intermediate-size groups of 
patients with similar treatment needs who otherwise do not qualify to participate in a clinical 
trial.61 Once more is known about the safety and potential effectiveness of a drug from ongoing 
or completed clinical trials, they also permit compassionate use for large groups of patients who 
do not have other treatment options available.62 Just as in clinical trials, these investigational 
drugs have not yet been determined by the FDA to be safe and effective. It is uncertain whether 
the drug will be effective in the treatment of a condition or if the patient will experience 
unexpected serious side effects.63 
Patients who don’t qualify for either clinical trials or an expanded access program, may 
be able to get the unapproved new drug by applying for single patient access.64 In order to gain 
single access, the patient’s doctor must first ask the drug company if the drug can be used for the 
                                                     
59 Id. 
60 Access to Investigational Drugs Outside of a Clinical Trial (Expanded Access), FDA (Feb. 24, 
2014),http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/AccesstoInvestigati
onalDrugs/ucm176098.html/ 
61 Id. 
62 Id. 
63 Id. 
64 Physician Request for an Individual Patient IND under Expanded Access for Non-emergency 
or Emergency Use, FDA (Sept. 17, 2013), 
http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/app
rovalapplications/investigationalnewdrugindapplication/ucm107434.htm 
patient and inquire as to whether the drug company will supply it. If the company agrees, the 
patient’s doctor works with the drug company to ask the FDA for approval of the drug for use by 
this one patient.65 
According to guidelines from the National Cancer Institute, most compassionate drug use 
is for patients who meet all of the following conditions: “have advanced disease, have used 
standard treatments that have not worked, are not eligible for any clinical trial that is in progress, 
have no other treatment options, have a type of cancer for which there’s reason to expect the 
investigational drug will help and are likely to have benefits that outweigh the risks involved.”66 
In a case like this, the doctor may consider trying to get a new, unapproved drug for a patient to 
see if it will help.67  
The FDA requires the doctor to send information about the patient explaining why the 
request is being made, the proposed treatment plan, and signed informed consent from the 
patient.68 The length of time it takes to get single patient access varies. But if it is an emergency, 
the FDA can complete the paperwork in 24 hours.69 
Before a patient or group of patients can get an unapproved new or experimental drug 
outside of a clinical trial, two things must happen. The owner, typically a drug company, of the 
new, unapproved drug must agree to allow the use of their drug outside of a clinical trial and the 
FDA medical officer in charge of overseeing the new drug’s development must approve the use 
of the drug for that person or group. 70 
The drug manufacturer and the patient’s doctor must make special arrangements to obtain 
                                                     
65 Id. 
66 Compassionate Drug Use, AMERICAN CANCER SOCIETY (July 9, 2013), 
http://www.cancer.org/treatment/treatmentsandsideeffects/clinicaltrials/compassionate-drug-use 
67 Id. 
68 Id. 
69 Id. 
70 Id. 
the drug for the patient and the FDA must authorize these arrangements.71 These safeguards are 
in place to avoid exposing patients to unnecessary risks.72 Manufacturers may not always be 
willing or able to provide access to a drug outside of their clinical trials.73 Currently, the easiest 
way to get an unapproved drug is through a clinical trial. This is problematic because many 
people with life-threatening diseases are unable to find suitable clinical trials, live far from 
research centers, or are not eligible for any studies being done.74 
Getting the drug through expanded access programs, or single-patient compassionate use is 
possible for some people though the process of satisfying each step necessary to be granted 
access can be long and frustrating for patients who do not have much time left. The drug 
companies policies and procedures can cause many obstacles along the way. For example, there 
may be very limited amounts of the drug; some companies establish lotteries to determine which 
patients will have treatment access, while others make the determination on a case-by-case 
basis.75 Once the drug is FDA-approved, it may be marketed and made widely available.  
Physicians may not always be able to seek expanded access for patients, depending on a 
patient’s medical history and the risks associated with taking an investigational drug.76 The 
physician must determine that the probable risk from the drug is not greater than the probable 
risk from the disease.77 Not all physicians are willing to manage the use of an investigational 
                                                     
71 Access to Investigational Drugs Outside of a Clinical Trial (Expanded Access), FDA (Feb. 24, 
2014),http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/AccesstoInvestigati
onalDrugs/ucm176098.html/ 
72 Id. 
73 Id.  
74 Compassionate Drug Use, AMERICAN CANCER SOCIETY (July 9, 2013), 
http://www.cancer.org/treatment/treatmentsandsideeffects/clinicaltrials/compassionate-drug-use 
75 Access to Investigational Drugs Outside of a Clinical Trial (Expanded Access), FDA (Feb. 24, 
2014),http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/AccesstoInvestigati
onalDrugs/ucm176098.html/ 
76 Id. 
77 Id. 
drug for patients in their care.  
Participating in a Phase I study is always risky and never offers a realistic likelihood of direct 
medical benefit. For example, a review of the risks and benefits of a new anticancer agent 
undergoing Phase I testing revealed that 1 out of every 200 patients enrolled died as a direct 
result of taking the drug, the death rate was closer to 1 in every 100 patients during the early part 
of the study.78 Only a very small percentage of patients (less than 4%) respond at all to these 
experimental drugs, and most of the responses are for very short period of time, sometimes a 
matter of weeks only and involve tumor shrinkage by only a small fraction.79 The benefit would 
not outweigh the risk if a patient were to request access to drugs that have not yet completed 
Phase I of the clinical trial.80 
Companies are not required to make their drug available through expanded access, or to 
make more of a drug for that purpose. Companies manufacture an investigational drug for the 
purpose of testing them in clinical trials, since that is the most effective and efficient way to 
determine whether the drugs work, and whether they are safe to use.81 Producing extra medicine 
for patients that are not in clinical trials can be costly for the drug company; especially because 
there is an inherent risk that the drug may never be approved.82 
Some companies provide the drug for free to patients, while other companies charge patients 
for costs associated with the manufacture of the drug.83 Most insurance companies will not pay 
for access to an investigational drug. In addition, there may be extra costs associated with 
                                                     
78 Eric X. Chen and Ian F. Tannock, Risks and Benefits of Phase 1 Clinical Trials Evaluating 
New Anticancer Agents, 292 JAMA 2150 (2004).  
79 Id. 
80 Id. 
81 Access to Investigational Drugs Outside of a Clinical Trial (Expanded Access), FDA (Feb. 24, 
2014),http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/AccesstoInvestigati
onalDrugs/ucm176098.html/ 
82 Id. 
83 Id. 
administration and monitoring of the investigational drug by healthcare professionals.84 
In 2009, the FDA revised its 1987 charging rule in order to take into account unanticipated 
circumstances concerning charging for investigational charges, to set forth criteria for charging 
under all three categories of expanded access and to specify the types of costs that can be 
recovered.85 One of the major goals the FDA had for the final rule was to extend its previous 
charging regulations to cover all types of expanded access programs and to describe more 
specifically the types of costs that sponsors may recover.86 
Sponsors typically are allowed to charge expanded access patients for the unapproved drug 
for one year from the time of FDA authorization, unless the FDA approves a different time 
period.87 Sponsors must meet three criteria for charging patients. First, they must justify the 
amount they plan to charge and obtain prior written approval from the FDA.88 Second, the 
sponsor must provide the FDA with "reasonable assurance that charging will not interfere with 
developing the drug for marketing approval."89 Third, the sponsor cannot charge patients who are 
not authorized to receive unapproved drugs through the expanded access program.90  
Despite these difficulties, compassionate drug use does happen. Actual use is not well-
documented, therefore there are limited numbers or statistics on how often it’s done, who’s doing 
                                                     
84 Id. 
85 Thomas Sullivan, FDA Expanded Access to Investigational Drugs for Treatment Use: Draft 
Guidance, POLICY AND MEDICINE (June 25, 2013, 5:09 AM), 
http://www.policymed.com/2013/06/fda-expanded-access-to-investigational-drugs-for-treatment-
use-draft-guidance.html. 
86 See Charging for Investigational Drugs, 74 Fed. Reg. 40,872, 40,872 (Aug. 13, 2009) (to be 
codified at 21 C.F.R. §312).  
87 See Id. at 40,899.  
88 Id.  
89 Id. 
90 See Id. 
it, or how well it’s working for patients.91 Compassionate use programs have the potential to 
positively impact terminally ill patients who are left with no other options after all treatments 
have been exhausted. As an initial step in expanding access, investigators, physicians and drug 
companies should provide better documentation of who is using the drug, how it is being used 
and the outcome of the use. By evaluating the types of uses and the types of patients using the 
drug, this information can be used to encourage patients to inquire about the drug and request 
access to participate in clinical trials.  
Once Phase I has been completed, it can be determined whether the drug is safe to check for 
efficacy. Therefore, the risk of harmful side effects in providing the drug outside of the trial is 
reduced. In the interest of patient autonomy, a terminally ill patient that is left with no other 
alternative for treatment should be able to determine whether the benefit of potentially treating 
the illness and making a last attempt to save or prolong their life outweighs the risk of the 
possibly harmful or fatal side effects. The question then turns on whether the patient has a 
fundamental right to make this decision and access this treatment.  
III. Right to Access 
The courts have addressed whether a fundamental right to access treatment exists. D.C. 
Circuit Judge Judith Rogers stated, “the prerogative asserted by the FDA, to prevent a terminally 
ill patient from using potentially life-saving medication to which those in Phase II clinical trials 
have access impinges upon an individual liberty deeply rooted in our Nation's history and 
tradition of self-preservation.” 92 
The Due Process Clause of the Fifth Amendment provides that “no person shall be deprived 
                                                     
91 Zuzanna Fimirska, Why Innovative Drug Access Can’t Wait, EYE FOR PHARMA (Apr. 24, 2014), 
http://social.eyeforpharma.com/patients/why-innovative-drug-access-cant-wait. 
92 Abigail Alliance for Better Access to Developmental Drugs v. Von Eschenbach, 469 F.3d 129 
(2006). 
of life, liberty, or property, without due process of law.”93 The United States Supreme Court has 
held that the protections of the Amendment guarantee more than fair process and has stated that 
the Clause provides heightened protection against government interference with certain 
fundamental rights and liberty interests, including the rights to marry, to have children, to direct 
the education and upbringing of one's children, to marital privacy, to use contraception, to bodily 
integrity, and to abortion.94  
As substantive rights are not set forth in the language of the Constitution, the United States 
Supreme Court has cautioned against expanding the substantive rights protected by the Due 
Process Clause because “guideposts for responsible decision-making in this unchartered area are 
scarce and open-ended.”95 
There is an additional and substantial concern that courts must also consider. By extending 
constitutional protection to an asserted right or liberty interest, the court, to a great extent, places 
the matter outside of the arena of public debate and legislative action.96 Thus, the Supreme Court 
has directed courts to exercise the utmost care whenever they are asked to break new ground in 
this field, to avoid the risk of the liberty protected by the Due Process Clause being distorted into 
the policy preferences of the courts' members. 
The United States Supreme Court has described its established method of substantive-due-
process analysis as having two primary features.97 First, the Court has regularly observed that the 
Due Process Clause specially protects those fundamental rights and liberties which are, 
objectively, deeply rooted in the nation's history and tradition and implicit in the concept of 
                                                     
93 Id. 
94 Id. at 137.  
95 Abigail Alliance for Better Access to Developmental Drugs v. Von Eschenbach, 495 F.3d 695 
(D.C. Cir. 2007). 
96 Id. at 702; see also Washington v. Glucksberg, 521 U.S. 702, 720-21, 117 S. Ct. 2258, 117 S. 
Ct. 2302, 138 L. Ed. 2d 772 (1997).  
97 Glucksberg, 521 U.S. at 720. 
ordered liberty, such that neither liberty nor justice would exist if they were sacrificed.98 Second, 
the Court has required in substantive-due-process cases a careful description of the asserted 
fundamental liberty interest.99 
“Creating constitutional rights to be free from regulation based solely upon a prior lack of 
regulation would undermine much of the modern administrative state, which, like drug 
regulation, has increased in scope as changing conditions have warranted.”100  
The United States Supreme Court has held that for the terminally ill, as for anyone else, a 
drug is unsafe if its potential for inflicting death or physical injury is not offset by the possibility 
of therapeutic benefit.101 The Food and Drug Administration's policy of limiting access to 
investigational drugs is rationally related to the legitimate state interest of protecting patients, 
including the terminally ill, from potentially unsafe drugs with unknown therapeutic effects.102  
D.C. Circuit Judge Thomas Griffith stated, “I have serious doubt about how a court can know, as 
a matter of constitutional law, that the lesser of two evils will be achieved by providing all 
terminally ill patients access to all Phase I experimental drugs, given the risks these drugs 
present.”103 
In 1979, the FDA had introduced specific rules allowing compassionate use of 
experimental therapies, terminally ill cancer patients and their spouses brought suit against the 
FDA to enjoin it from interfering in the marketing and distribution of a drug called Laetrile.104 
Laetrile was an extract of apricot pits and almonds, available outside of the U.S. and widely 
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believed to be effective in the treatment of cancer.105 Parties to the suit believed Laetrile was 
their last and only option. The FDA had denied approval for marketing of the drug and was 
waiting for greater clinical research data on efficacy and safety.106 
Recognizing the limited options that terminal cancer patients faced, the U.S. Supreme 
Court in Rutherford stood by the FDA actions and concluded that the right to access unproven 
therapies did not exist in this case.107 Acknowledging that there is a clear protected right to 
refuse life-saving treatment, the Court distinguished this from a positive right to access a 
particular treatment or medication.108 The Court argued that a drug is as unsafe for the terminally 
ill as for anyone else if its prospects of death and physical injury are not outweighed by its 
potential for benefit.109 The FDA had not yet found evidence that Laetrile was safe and effective. 
Furthermore, the Court asserted, the government, specifically the FDA, has an interest in 
regulating unsafe drugs and protecting the public’s health.110 
Returning to the case of Abigail Alliance v. Eschenbach, in which the Court addressed 
whether the Constitution provides terminally ill patients a right of access to experimental drugs 
that have passed limited safety trials but have not been proven safe and effective. The Alliance 
argued that patients have a right to decide, for themselves, whether to take an investigational 
drug that the FDA has approved for clinical trials.111 The FDA argued that the requested 
expanded access would upset the appropriate balance that the FDA is seeking to maintain, by 
giving almost total weight to the goal of early availability and giving little recognition to the 
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importance of marketing drugs with reasonable knowledge for patients and physicians of their 
likely clinical benefit and their toxicity.112 
The district court held there is no such right. The FDA reserves the right, however, to 
deny any treatment IND request if the agency believes there is no “reasonable basis” to conclude 
that the drug is effective or if granting the request “would expose the patient to an unreasonable 
and significant additional risk of illness or injury.”113 Sponsors may not profit from any approved 
treatment IND program and may only “recover costs of manufacture, research, development, and 
handling of the investigational drug.”114  
The panel majority in Abigail ruled that “mentally competent, terminally ill adult patients 
with no government-approved treatment option have a constitutional right to access potentially 
life-saving investigational new drugs that the FDA has determined, after Phase I trials, are 
sufficiently safe for expanded human trials, post-Phase I investigational new drug.”115  In their 
reasoning, the panel relied heavily on treatises and law review articles, the panel majority 
explained that “a right of control over one’s body has deep roots in the common law” and that 
“barring a terminally ill patient from the use of a potentially life-saving treatment impinges on 
the right of self-preservation.”116 
Second, the panel majority observed that government regulation of drugs based on 
concerns over efficacy, as opposed to safety, is of recent origin, because Congress has regulated 
access to new drugs on efficacy grounds only since 1962.117  Third, the panel majority argued, 
“the claimed right is implied by” the Supreme Court’s ruling which recognized that the Due 
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Process Clause “protects a person’s right to refuse life-sustaining treatment.”118 The panel 
majority observed that “if there is a protected liberty interest in self-determination that includes a 
right to refuse life-sustaining treatment, even though this will hasten death, then the same liberty 
interest must include the complementary right of access to potentially life-sustaining medication, 
in light of the explicit protection accorded ‘life.’119 
In 2007, the U.S. Court of Appeals for the District of Columbia reheard the case en banc. 
The Court issued an 8-2 decision against the Abigail Alliance, reversing the previous panel 
decision, thereby upholding the previous court decision that found there is no constitutional right 
to unapproved drugs by terminally ill patients.120 
After determining that there is not a fundamental right to access, the court considered 
whether the common law doctrines of necessity, intentional interference, and self-defense 
supported a fundamental right of self-preservation.121 The Court focused on whether an 
unapproved drug of uncertain safety and efficacy could be considered necessary for prolonging 
the life of a terminally ill patient. 
Necessity provides an individual with a defense when "physical forces beyond the actor's 
control rendered illegal conduct the lesser of two evils."122 There are two factors to consider 
when applying the necessity defense; the first is the amount of certainty needed to trust that a 
particular means of self-defense will be useful, and the second factor is the desperation that may 
drive one to use a means of self-defense even if it is unlikely to be effective.123 A terminally ill 
patient who has exhausted all of the available treatments and therapies could have a good faith 
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belief that an unapproved drug is the only thing that could save her life and is therefore necessary 
for prolonging her life, despite evidence that the drug is unlikely to be effective.  
Relying on United States v. Oakland Cannabis Buyers' Cooperative,124 the majority 
dismissed the claim for necessity because Congress has already expressly eliminated a necessity 
defense in the context of access to unapproved drugs.125 The Court stated "under any conception 
of legal necessity, one principle is clear: the defense cannot succeed when the legislature itself 
has made a determination of values. Congress may limit or even eliminate a necessity defense 
that might otherwise be available. That is precisely what the FDCA has done."126 
Through the FDCA, Congress explicitly restricted patients' access to only those drugs 
that were approved as safe and effective, thereby eliminating a necessity defense for terminally 
ill patients.127 In denying the necessity defense, the majority also relied on the fact that there is 
significant uncertainty regarding whether unapproved drugs can save patients' lives. 
One of the legal elements of the necessity defense is that "the individual must believe in 
good faith that the unlawful act will remedy the greater evil."128. Given the uncertainty 
surrounding the safety and efficacy of drugs in clinical trials, it was argued that terminally ill 
patients cannot assert in good faith that such drugs are necessary to save their lives.129 There 
cannot be a viable claim to exercise the right to necessity without some degree of certainty that 
the treatment used will actually save the patient's life.  
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Congress has prohibited general access to experimental drugs, and has prescribed in detail 
how experimental drugs may be studied and used by the scientific and medical communities. 130 
The United States Supreme Court has concluded that the common law defense of necessity 
remains controversial and cannot override a value judgment already determined by the 
legislature.131 
Abigail Alliance also attempted to assert that the tort of intentional interference provides 
support for a right to access unapproved drugs. This tort consists of a tortfeasor preventing an 
individual from providing aid that is necessary to another's bodily security.132 It was argued that 
the tort of intentional interference does provide a basis for an individual’s interest in self-
preservation by accessing unapproved drugs. This is because, in some cases, investigational 
treatments are the only means terminally ill patients have to prolong their lives.133 
However, the majority concluded that withholding unapproved drugs is not intentional 
interference because drugs that have not been proven safe and effective cannot be considered 
necessary to bodily security.134 For these reasons, the FDA regulations that restrict access to 
unapproved drugs do not prevent patients from receiving necessary aid, and intentional 
interference does not help establish a constitutional right to access. 
Self-defense and a right to self-preservation are related concepts. A claim of self-defense 
can be made "when a victim is being attacked by an aggressor and uses reasonable force to 
overcome immediate danger."135According to Abigail Alliance, the correlation between medical 
self-defense and traditional self-defense is not effected by the fact that drugs pose risks of side 
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effects because an act of traditional self-defense may also pose risks.136 For example, a victim's 
attempt to defend herself may anger her attacker, leading her attacker to harm her more 
egregiously than he otherwise would have.137 Under this reasoning, terminally ill patients should 
be permitted to access unapproved drugs even if those drugs pose serious risks. 
The Court did not agree with this reasoning stating "terminally ill patients cannot fairly 
be characterized as using reasonable force to defend themselves when they take unproven and 
possibly unsafe drugs."138 
Following the decision in Abigial, the trial court in Gunvalson v. PTC Therapeutics, Inc., 
issued an injunction which was later reversed, requiring a drug company, PTC Therapeutics, to 
provide an experimental drug to a patient outside of the context of a clinical trial.139 Under the 
ruling, Gunvalson, would be able to start taking a drug intended to treat Duchenne muscular 
dystrophy, a rare and fatal disease that strikes boys and young men.140 The developer, PTC 
Therapeutics contended that Jacob Gunvalson did not meet the criteria to be a part of the drug’s 
clinical trial. The drug was still in phase II of clinical trials.141 
The facts of the case set it apart and illustrate other ways in which the argument for 
expanded access may be denied. From the time Jacob was diagnosed with Duchenne Muscular 
Dystrophy, his mother worked to raise awareness as well as money for research, even appearing 
before Congress to lobby for government funding.142 In the course of her efforts, she came in 
contact with the Vice President of PTC Therapeutics. Jacob and his mother were in close 
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communications with PTC Therapeutics’ management and staff on a regular basis.143 This does 
not occur in the usual clinical trial situation; typically the patient only has contact with the 
investigators and the site where the trial is being conducted, but not the drug company sponsor. 
As PTC Therapeutics was proceeding to the clinical trial stage of product development, his 
mother was helping the company obtain funding for the trials.144 In early 2006, PTC 
Therapeutics began a Phase II trial that Jacob did not participate in because he was on another 
medication, which was still working for him.145  
By 2008, Jacob’s condition was deteriorating and his current medication was no longer 
working. PTC Therapeutics was conducting additional trials, but determined that Jacob was not 
eligible to participate in the study.146 PTC announced that the company's investigational drug for 
the treatment of genetic disorders due to nonsense mutations was featured in a symposium at the 
Third Annual Congress of Myology 2008.147 Dr. Thomas Voit, M.D., Medical and Scientific 
Director of the Myology Institute, stated that the drug “represents a promising new therapy for 
Duchenne muscular dystrophy and Becker muscular dystrophy as there are currently no available 
treatments that address the underlying cause of this disease.”148 He went on to say that "the Phase 
2b PTC124 clinical trial sets a gold standard for future clinical trials in muscular dystrophies."149  
The plaintiffs sought a preliminary injunction in the U.S. District Court requiring PTC 
Therapeutics to provide the drug. In its decision granting the injunction, the court held that in 
light of the plaintiff and his mother’s unique relationship with senior management, the company, 
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whether it intended to or not, had made an enforceable promise to provide the drug and could not 
deny its compassionate use.150  The United States Court of Appeals for the Third Circuit, 
however, vacated the decision and remanded the case for further proceedings.151 
The Appellate Court ruled that the plaintiffs had not shown that PTC Therapeutics had 
made a clear and definite promise, nor did they prove that the reason Jacob did not enroll in the 
2006 trial was his reasonable reliance on the alleged promise.152 With his health deteriorating, 
Jacob was ultimately denied access to the drug. Unlike the previous cases, the Gunvalson’s did 
not attempt to assert a fundamental constitutional right to the experimental drug yet they were 
still unsuccessful in gaining access to the clinical trial. This further case illustrates the difficulty 
terminally ill patient’s face in trying to gain access to an unapproved therapy and the Court’s 
reluctance in granting access to investigational drugs despite evidence of positive clinical 
progress. 
IV. Recommendations  
The Abigail Alliance case and other claims for access involve terminally ill people who 
were unable to obtain access to expanded use programs and clinical trials. One solution might be 
to change the approach to clinical trials, perhaps by expanding the inclusion criteria for Phase II 
and Phase III trials. The purpose of current Phase II trials and Phase III trials would not change. 
What would change would be the number of participants allowed access to the experimental drug 
through Phase II trials.153 Phase II studies could be more useful if they studied a larger sample 
size and had less restrictive inclusion and exclusion criteria to broaden the pool of patients 
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eligible to participate.  
"In general, Phase II trials are smaller than they ought to be" for obtaining a precise 
estimated response rate.154 The precision of the estimated response rate is important for 
designing Phase III of the clinical trial.155 Phase III trials are comparative trials that focus on 
efficacy, while still monitoring for any adverse events. The FDA will not make a final safety and 
efficacy determination until these trials are completed.156 Because the precision of the estimated 
response rate is largely attributed to the enrollment size of Phase II trials, it is common for 
investigational drugs that show promise after completing Phase II trials to fail Phase III trials.157 
Small Phase II trials produce drug responses that are not typically representative of the same 
drug responses in the larger Phase III trials.158 Increasing the number of patients in a Phase II 
study would provide more accurate information as to the response rate and will show better 
indication if the drug will fail Phase III trials. 
Making the inclusion criteria less restrictive for Phase II and III trials and increasing the 
number of patients enrolled in those phases might produce both valuable scientific knowledge 
and prevent expanded access programs from interfering with clinical investigation.159 It would 
also ensure that individuals being exposed to unapproved drugs were provided the careful safety 
monitoring involved in clinical trials.  
In addition, requiring sponsors to include more individuals in clinical trials might save 
sponsors money while providing much-needed data on an unapproved therapy. Better data 
collection through more inclusive Phase II clinical trials could be cost effect in that it would 
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prevent companies from conducting expensive and unsuccessful Phase III trials.160 
Although tens of thousands of patients have been enrolled in expanded access programs, 
the data collected from these programs have been incomplete, with information about less than 
half of the patients involved being sent back to the FDA. 161  The information that has been 
returned to the FDA has not been very useful. Unless expanded access programs can be better 
designed to produce data of some value, they cannot substitute for clinical trials on terminally ill 
patients. Clinical trials provide a systematic approach that serves to promote patient safety and 
adequate data collection.  
Clinical trials with strict exclusion criteria make it difficult, if not impossible, to obtain 
systematic data on subpopulations of patients with complex conditions before a drug is released 
for use by the population at large.162 Researchers have advocated for clinical trials that "include a 
more diverse study population to enroll patients in the trial with characteristics that reflect the 
range and distribution of patients observed in clinical practice."163 “Unlike smaller studies with 
relatively homogenous groups of people, larger, more diverse clinical trials can provide enough 
information to examine the effects of interventions on subgroups based on race, age, gender, and 
stage of disease.”164 More information about the effect of the drug on different subsections of the 
population prior to widely marketing that drug is clearly preferable for public health reasons.165 
Sponsors may be reluctant to include terminally ill patients in clinical trials because this 
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could potentially increase the number of adverse events in the trial, making it more difficult to 
collect data and demonstrate the effect of the treatment.166 The risk inherent in including people 
with terminal illness is the possibility that the disease, and not the drug, will cause them to 
experience morbidity or mortality. It may be more difficult to determine the cause of negative 
outcomes. The researchers would be tasked with determining whether the drug or the disease 
caused the adverse event.  
To address these concerns the sponsors could create a subsection of the clinical trial that 
would include only those patient’s that are terminally ill. One group would consist of those 
research subjects who would traditionally fit under the inclusion and exclusion criteria and the 
subsection of expanded access patient’s would consist of those who would not traditionally fit 
into the strict criteria of the primary group.  
The analysis of the data would focus on subjects who meet the traditional inclusion 
criteria, and the secondary analysis would be supplemental and include information from the 
subsection of terminally ill research subjects. Including patients that are in more advanced stages 
of the disease may make it more time-consuming and difficult to interpret the data. However, it 
has been found that the current inclusion and exclusion criteria is so strict that it is producing 
inadequate information for policymakers, physicians, and patients by excluding sicker patients or 
more representative members of the population.167  
V. Conclusion 
An effective approach to expanded access is to allow very limited access to unapproved 
drugs outside of clinical trials while expanding eligibility for clinical trials in order to ensure that 
more people receive access in a controlled and systematic fashion. For eligible patients that are 
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unable to participate in the clinical trial because they live too far away or for patient’s who have 
been granted access through individual use, these patients could participate in the trial remotely. 
They could continue to see their usual health care providers while being enrolled in the clinical 
study for purposes of safety, monitoring and data collection. The approved health care provider 
should comply with the study protocol of the trial, monitor the patient’s use and electronically 
report all records and findings to the researchers. By having the participant's current health care 
provider work with the research team, the participant will receive the benefit of the protections 
and close supervision of the clinical trial study protocol while continuing to receive the same 
health care that was provided prior to enrolling in the study. By using the patient’s current health 
care provider the participant can also be sure that the study protocol does not conflict with other 
medications or treatments. Creating a system in which clinical trials and compassionate use 
programs work closely together under the same study protocol, would promote patient safety 
when using the drug outside of the clinical trial, produce valuable scientific knowledge through 
improved data collection and prevent expanded access programs from interfering with clinical 
investigation. 
 
